Shown in Table 4, ALK inhibitors showed superior efficacy in the treatment of ALK-positive NSCLC compared with chemotherapy in OS (hazard ratio (HR), 0.83; 95% CI, 0.72–0.97; I2 = 0%; n = 5), PFS (HR, 0.43; 95% CI, 0.35–0.54; I2 = 65%; n = 6), ORR (rate difference (RD), 23%; 95% CI, 17–29, I2 = 53%; n = 8), and DCR (RD, 10%; 95% CI, 4–16, I2 = 45%; n = 6). This evidence concerns the gene ALK and non-small cell lung carcinoma.